Therapies using non-natural amino acids and polypeptides

Details Therapies using non-natural amino acids and polypeptides Therapies using non-natural amino acids and polypeptides

2005-12-21

2009-12-29

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S013800, C514S014800, C514S015800, C530S324000, C530S325000, C530S326000

Reexamination Certificate

active

07638491

ABSTRACT:
Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

REFERENCES:
patent: 4680311 (1987-07-01), Watanabe et al.
patent: 5364840 (1994-11-01), Basava et al.
patent: 5484771 (1996-01-01), Beaulieu et al.
patent: 6337191 (2002-01-01), Swartz et al.
patent: 6344483 (2002-02-01), Hallinan et al.
patent: 6608183 (2003-08-01), Cox, III
patent: 6608196 (2003-08-01), Wang et al.
patent: 6900218 (2005-05-01), Wang et al.
patent: 7332571 (2008-02-01), Miao et al.
patent: 7385028 (2008-06-01), Miao et al.
patent: 2002/0065418 (2002-05-01), Beaulieu et al.
patent: 2002/0081660 (2002-06-01), Swartz et al.
patent: 2003/0072746 (2003-04-01), Miller
patent: 2003/0082575 (2003-05-01), Schultz et al.
patent: 2003/0108885 (2003-06-01), Schultz et al.
patent: 2008/0153979 (2008-06-01), Miao et al.
patent: 2008/0177027 (2008-07-01), Miao et al.
patent: 2008/0177038 (2008-07-01), Miao et al.
patent: 2008/0182968 (2008-07-01), Miao et al.
patent: 2008/0182969 (2008-07-01), Miao et al.
patent: 2008/0213840 (2008-09-01), Miao et al.
patent: 2008/0268518 (2008-10-01), Miao et al.
patent: 2008/0268519 (2008-10-01), Miao et al.
patent: 2110543 (1994-06-01), None
patent: WO-90-05785 (1990-05-01), None
patent: WO-00-55353 (2000-09-01), None
Disorders from the Merck Manual.
Diseases from the Merck Manual.
Dementia including Alzheimer's Disease from the Merck Manual.
Mattson MP, Pathways towards and away from Alzheimer's disease, Nature, 2004, 430: 631-639.
Rudinger J, Characteristics of the amino acids as components of a peptide hormone sequence, Peptide Hormones, 1976, J.A. Parsons, MA Edition, National Institutes for Medical Research.
Designing Custom Peptides, SIGMA, accessed Dec. 16, 2004.
Berendsen HJC, A Glimpse of the Holy Grail?, Science, 1998, 282: 642-643.
Voet and Voet, Biochemistry, Second Edition, 1995, 235-241.
GenBank Accession No. CAA41788 (Fibroblast Growth Factor).
GenBank Accession No. CAA26095 (erythropoietin).
GenBank Accession No. CAA34902 (epidermal growth factor).
Introduction to Cancer from Merck Manual, p. 1. Accessed Mar. 5, 2008.
Clinical Aspects of Cancer from Merck Manual, pp. 1-4. Accessed Feb. 20, 2008.
Auerbach R, Akhtar N, Lewis RL, Shinners BL. “Angiogenesis assays: Problems and pitfalls”, Cancer and Metastasis Reviews, 2000, 19: 167-172.
Gura Trisha. “Systems for Identifying New Drugs Are Often Faulty”, Cancer Models, Science, Nov. 7, 1997, 278: 1041-1042.
Jain RK. “Barriers to Drug Delivery in Solid Tumors”, Scientific American, Jul. 1994, 58-65.
Steinman L and Zamvil SS. “How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis”, Annals of Neurology, 2006, 60: 12-21.
Sriram S and Steiner I. “Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis”, Annals of Neurology, 2005, 58: 939-945.
Short Stature from http://www.emedicine.com/PED/topic2087.htm, pp. 1-21. Accessed Nov. 30, 2008.
Ngo JT, Marks J, Karplus M. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problems and Tertiary Structure Prediction, K Merc, Jr. and S. Le Grand, Editors, Birkhauser Boston, 1994.
Bradley CM, Barrick D. “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch ANkyrin Domain to Analogous Alanine Substitutions in Each Repeat”, Journal of Molecular Biology, 2002, 324: 373-386.
Rodriguez EC, Winans KA, King DS, Bertozzi CR, “A Strategy for the Chemoselective Synthesis of O-linked Glycopeptides with Native Sugar-Peptide Linkages,” Journal of American Chemical Society, 1997, 119: 9905-9906.
Anderson et al., “Exploring the Limits of Codon and Anticodon Size,” Chem. And Biol. 9:237-244 (2002).
Bain, J.D. et al., “Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide,” J. Am. Chem. Soc. 111:8013-8014 (1989).
Boles, J.O. et al., Nat. Struct. Biol. 1:5:283-284 (1994).
Brunner, J., “New Photolabeling and crosslinking methods,” Ann. Rev. Biochem. vol. 62, pp. 483-514 (1993).
Budisa, N. et al., Eur. J. Biochem. 230:788-796 (1995).
Budisa, N. et al., FASEB J. 13:41-51 (1999).
Budisa, N. et al., J. Mol. Biol. 270:616-623 (1997).
Carrasco, M.R. and Brown, R.T., J. Org. Chem. 68:8853-8858 (2003).
Chaiken, I.M., “Semisynthetic peptides and proteins,” CRC Critical Reviews in Biochemistry, pp. 255-301 (1981).
Chin, J.W. and Schultz, P.G., (2002) ChemBioChem 11:1135-1137.
Chin, J. W. et al, (2002) J. Am. Chem. Soc. 124:9026-9027 (2002).
Chin, J.W. et al., (2002) PNAS USA 99:17:11020-11024.
Chin, J. et al., (2003) Science 301:964-7.
Corey, D.R. and Schult, P.G., “Generation of a hybrid sequence-specific single-stranded deoxyribonuclease,” Science, vol. 238, pp. 1401-1403 (1987).
Cornish, V.W., Mendel, D. and Schultz, P.G., Angew. Chem. Int. Ed. Engl. 34:621 (1995).
Cornish, V.W., et al., J. Am. Chem. Soc. 118:8150-8151 (1996).
Crick, F.J.C., et al., “General nature of the genetic code for proteins,” Nature vol. 192, No. 4809, pp. 1227-1232(1961).
Dennis et al., J. Biol. Chem. 277:38:35035-35043 (2002).
Doring, V. et al., Science 292:501-504 (2001).
Dougherty, (2000), “Unnatural Amino Acids as Probes of Protein Structure and Function,” Curr. Op. in Chem. Biol. 4:645-652.
Duewel, H. et al., Biochemistry 36:3404-3416 (1997).
Ellman, J.A. et al, “Biosynthetic method for introducing unnatural amino acidssite-specifically into proteins,” Methods in Enz. vol. 202, pp. 301-336 (1992).
Ellman, J.A. et al, “Site-specific incorporation of novel backbone structures into proteins,” Science vol. 255, pp. 197-200 (1992).
England, P.M. et al., Cell 96:89-98 (1999).
Forster, A. et al., PNAS USA 100:11:6353-6357 (2003).
Frankel, A. et al., Chem. & Biol. 10:1043-1050 (2003).
Furter, R., Protein Sci. 7:419-426 (1998).
Gallivan, J.P. et al., Chem. Biol. 4:10:739-749 (1997).
Geoghegan, K. and Stroh, J., Bioconjug. Chem. 3:138-146 (1992).
Guckian and Kool, Angew. Chem. Int. Ed. Engl. 36:24:2825-2828 (1998).
Hang, H. and Bertozzi, C., Acc. Chem. Res. 34:9:727-736 (2001).
Hamano-Takaku, F. et al., J. Biol. Chem. 275, No. 51:40324-40328 (2000).
Hendrickson, W.A., et al., EMBO J. 9:5:1665-1672 (1990).
Hirao et al., “An unnatural base pair for incorporating amino acid analogues into protein,” Nature Biotech. 20:177-182 (2002).
Hofmann, K. and Bohn, H., “Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment,” J. Am. Chem., vol. 88, No. 24, pp. 5914-5919 (1966).
Hohsaka et al. J. Am. Chem. Soc. 121:34-40 (1999).
Hohsaka et al., J. Am. Chem. Soc. 121:12194-12195 (1999).
Ibba, M. et al., Biochemistry 33:7107-7112 (1994).
Ibba, M. and Hennecke, H., FEBS Lett. 364:272-275 (1995).
Jackson, D.Y. et al., “A Designed Peptide Ligase for Total Synthesis of Ribonuclease A with Unnatural Catalytic Residues,” Science, vol. 266, pp. 243-247 (1994).
Jencks, W.P., J. Am. Chem. Soc. 81, pp. 475-481 (1959).
Kaiser, E.T. et al., “The

Affiliated with

Also associated with

Rating

Therapies using non-natural amino acids and polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapies using non-natural amino acids and polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapies using non-natural amino acids and polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4125909